Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer

This publication has 22 references indexed in Scilit:

• Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
  Cancer Discovery, 2018
• Bone biopsy protocol for advanced prostate cancer in the era of precision medicine
  Cancer, 2017
• Clonal hematopoiesis
  Seminars in Hematology, 2017
• Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
  JAMA Oncology, 2016
• Clinical outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequences in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study
  Annals of Oncology, 2016
• Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
  Journal of Clinical Oncology, 2016
• Integrative Clinical Genomics of Advanced Prostate Cancer
  Cell, 2015
• Burden of Disease Matters When It Comes to Systemic Therapy for Prostate Cancer
  European Urology, 2015
• Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
  Journal of Clinical Oncology, 2014
• Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy
  Prostate Cancer and Prostatic Diseases, 2013